A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction

Haematologica

Volumn 98, Issue 9, 2013, Pages 1407-1413

  Shinohara, Yoshinori ^a   Takahashi, Naoto ^a   Nishiwaki, Kaichi ^b   Hino, Masayuki ^c   Kashimura, Makoto ^d   Wakita, Hisashi ^e   Hatano, Yoshiaki ^f   Hirasawa, Akira ^g   Nakagawa, Yasuaki ^h   Itoh, Kuniaki ⁱ   Masuoka, Hidekazu ^b   Aotsuka, Nobuyuki ^e   Matsuura, Yasuhiro ^e   Takahara, Sinobu ^b   Sano, Koji ^b   Kuroki, Jun ^j   Hata, Tomoko ^k   Nakamae, Hirohisa ^c   Mugitani, Atsuko ^l   Miyazaki, Yasushi ^k   Niioka, Takenori ^m   Miura, Masatomo ^m   Sawada, Kenichi ^a   more..

^a AKITA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d Matsudo City Hospital   (Japan)

^e NARITA RED CROSS HOSPITAL   (Japan)

^f Yamamoto Kumiai General Hospital   (Japan)

^g YOKOHAMA ROSAI HOSPITAL   (Japan)

^h JAPANESE RED CROSS MEDICAL CENTER   (Japan)

ⁱ NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^j Yuri Kumiai General Hospital   (Japan)

^k NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^l Fuchu Hospital   (Japan)

^m AKITA UNIVERSITY HOSPITAL   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; BREAST CANCER RESISTANCE PROTEIN; IMATINIB;

ADULT; AGED; ARTICLE; CHRONIC MYELOID LEUKEMIA; DRUG RESPONSE; FEMALE; FLOW CYTOMETRY; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; REMISSION;

ADULT; AGED; AGED, 80 AND OVER; BENZAMIDES; FEMALE; HUMANS; INTERNATIONALITY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; REAL-TIME POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84883628043     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.085167     Document Type: Article

References (49)

1. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-51.
2. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol. 2011;29(5):573-82.
3. Thoennissen NH, Krug UO, Lee DH, Kawamata N, Iwanski GB, Lasho T, et al. Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood. 2010;115(14):2882-90.
4. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387-97.
5. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108(10):3472-6.
6. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Masse A, et al. Mutation in TET2 in myeloid cancers. The N Eng J Med. 2009;360(22):2289-301.
7. Carbuccia N, Murati A, Trouplin V, Brecqueville M, Adelaide J, Rey J, et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia. 2009;23(11): 2183-6.
8. Abdel-Wahab O, Manshouri T, Patel J, Harris K, Yao J, Hedvat C, et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res. 2010;70(2):447-52.
9. Grand FH, Hidalgo-Curtis CE, Ernst T, Zoi K, Zoi C, McGuire C, et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood. 2009;113(24):6182-92.
10. Jager R, Gisslinger H, Passamonti F, Rumi E, Berg T, Gisslinger B, et al. Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. Leukemia. 2010; 24(7):1290-8.
11. Oh ST, Simonds EF, Jones C, Hale MB, Goltsev Y, Gibbs KD Jr, et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood. 2010; 116(6):988-92.
12. Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Gen. 2010;42(8):722-6.
13. Esteller M. Epigenetics in cancer. N Engl J Med. 2008;358(11):1148-59.
14. Suzuki MM, Bird A. DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Gen. 2008;9(6):465-76.
15. Agirre X, Vilas-Zornoza A, Jimenez-Velasco A, Martin-Subero JI, Cordeu L, Garate L, et al. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res. 2009;69(10):4443-53.
16. Martin-Subero JI, Ammerpohl O, Bibikova M, Wickham-Garcia E, Agirre X, Alvarez S, et al. A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms. PloS one. 2009;4(9):e6986.
17. Alvarez S, Suela J, Valencia A, Fernandez A, Wunderlich M, Agirre X, et al. DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemia. PloS one. 2010; 5(8):e12197.
18. Perez C, Martinez-Calle N, Martin-Subero JI, Segura V, Delabesse E, Fernandez-Mercado M, et al. TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia. PloS one. 2012;7(2):e31605.
19. Battaglia S, Maguire O, Campbell MJ. Transcription factor co-repressors in cancer biology: roles and targeting. Int J Cancer. 2010;126(11):2511-9.
20. Zhao JL, Rao DS, Boldin MP, Taganov KD, O'Connell RM, Baltimore D. NF-kappaB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies. Proc Natl Acad Sci USA. 2011;108(22):9184-9.
21. Gringhuis SI, den Dunnen J, Litjens M, van Het Hof B, van Kooyk Y, Geijtenbeek TB. Ctype lectin DC-SIGN modulates Toll-like receptor signaling via Raf-1 kinase-dependent acetylation of transcription factor NFkappaB. Immunity. 2007;26(5):605-16.
22. Morlon A, Munnich A, Smahi A. TAB2, TRAF6 and TAK1 are involved in NFkappaB activation induced by the TNFreceptor, Edar and its adaptator Edaradd. Hum Mol Genet. 2005;14(23):3751-7.
23. Madkaikar M, Mhatre S, Gupta M, Ghosh K. Advances in autoimmune lymphoproliferative syndromes. Eur J Haematol. 2011; 87(1):1-9.
24. Brenner O, Levanon D, Negreanu V, Golubkov O, Fainaru O, Woolf E, et al. Loss of Runx3 function in leukocytes is associated with spontaneously developed colitis and gastric mucosal hyperplasia. Proc Natl Acad Sci USA. 2004;101(45):16016-21.
25. Shoemaker SG, Hromas R, Kaushansky K. Transcriptional regulation of interleukin 3 gene expression in T lymphocytes. Proc Natl Acad Sci USA. 1990;87(24):9650-4.
26. Allioli N, Vincent S, Vlaeminck-Guillem V, Decaussin-Petrucci M, Ragage F, Ruffion A, et al. TM4SF1, a novel primary androgen receptor target gene over-expressed in human prostate cancer and involved in cell migration. The Prostate. 2011;71(11):1239-50.
27. Deneberg S. Epigenetics in myeloid malignancies. Methods Mol Biol. 2012;863:119-37.
28. Hao JS, Shan BE. Immune enhancement and anti-tumour activity of IL-23. Cancer Immunol Immunother CII. 2006;55(11): 1426-31.
29. Belladonna ML, Renauld JC, Bianchi R, Vacca C, Fallarino F, Orabona C, et al. IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells. J Immunol. 2002;168(11):5448-54.
30. Feng XM, Chen XL, Liu N, Chen Z, Zhou YL, Han ZB, et al. Interleukin-27 upregulates major histocompatibility complex class II expression in primary human endothelial cells through induction of major histocompatibility complex class II transactivator. Hum Immunol. 2007; 68(12):965-72.
31. Patsos G, Germann A, Gebert J, Dihlmann S. Restoration of absent in melanoma 2 (AIM2) induces G2/M cell cycle arrest and promotes invasion of colorectal cancer cells. Int J Cancer. 2010;126(8):1838-49.
32. Heyn H, Esteller M. DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet. 2012;13(10):679-92.
33. De S, Shaknovich R, Riester M, Elemento O, Geng H, Kormaksson M, et al. Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity. PLoS Genetics. 2013;9(1):e1003137.
34. Jelinek J, Gharibyan V, Estecio MR, Kondo K, He R, Chung W, et al. Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia. PloS one. 2011;6(7):e22110.
35. Barrio S, Gallardo M, Albizua E, Jimenez A, Rapado I, Ayala R, et al. Epigenomic profiling in polycythaemia vera and essential thrombocythaemia shows low levels of aberrant DNA methylation. J Clin Pathol. 2011;64(11):1010-3.
36. Nischal S, Bhattacharyya S, Christopeit M, Yu Y, Zhou L, Bhagat TD, et al. Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms. Cancer Res. 2013; 73(3):1076-85.
37. Taylor KH, Pena-Hernandez KE, Davis JW, Arthur GL, Duff DJ, Shi H, et al. Large-scale CpG methylation analysis identifies novel candidate genes and reveals methylation hotspots in acute lymphoblastic leukemia. Cancer Res. 2007;67(6):2617-25.
38. Dunwell TL, Hesson LB, Pavlova T, Zabarovska V, Kashuba V, Catchpoole D, et al. Epigenetic analysis of childhood acute lymphoblastic leukemia. Epigenetics. 2009; 4(3):185-93.
39. Skov V, Larsen TS, Thomassen M, Riley CH, Jensen MK, Bjerrum OW, et al. Whole-blood transcriptional profiling of interferoninducible genes identifies highly upregulated IFI27 in primary myelofibrosis. Eur J Haematol. 2011;87(1):54-60.
40. Braun T, Carvalho G, Coquelle A, Vozenin MC, Lepelley P, Hirsch F, et al. NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood. 2006;107(3):1156-65.
41. Shimizu R, Yamamoto M. Contribution of GATA1 dysfunction to multi-step leukemogenesis. Cancer Sci. 2012;103(12):2039-44.
42. Trinchieri G. Type I interferon: friend or foe? J Exp Med. 2010;207(10):2053-63.
43. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev. 2001;14(4):778-809.
44. Kiladjian JJ, Mesa RA, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood. 2011;117(18):4706-15.
45. Bekisz J, Baron S, Balinsky C, Morrow A, Zoon KC. Antiproliferative Properties of Type I and Type II Interferon. Pharmaceuticals (Basel). 2010;3(4):994-1015.
46. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov. 2007;6(12):975-90.
47. Li J, Zhao Q, Xing W, Feng J, Wu H, Li H, et al. Interleukin-27 enhances the production of tumour necrosis factor-alpha and interferon-gamma by bone marrow T lymphocytes in aplastic anaemia. Br J Haematol. 2011;153(6):764-72.
48. Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood. 2012;119(14):3219-25.
49. Brandt SJ, Koury MJ. Regulation of LMO2 mRNA and protein expression in erythroid differentiation. Haematologica. 2009; 94(4): 447-8.